BioSpace News Archive

Biogen gained exclusive ex-U.S. rights to Ampyra in 2009 and is selling the drug under the brand name Fampyra in international markets.

After a quiet start to 2024, the FDA is expected to decide on three applications over the next two weeks, including one for a nasal powder migraine treatment.

There seems to be decidedly positive sentiment regarding biopharma in 2024—perhaps a harbinger of things to come this year coming off a topsy-turvy 2023.

As JPM week draws close, Lilly CEO David Ricks talks about what he thinks is in store for the biopharma industry.

Dropping the potential Cytokinetics buy runs contrary to Novartis’ recent dealmaking frenzy, which included the acquisition of Calypso and three research collaborations.

The agency nevertheless said that it could not definitively rule out a small risk of suicidal ideation associated with GLP-1 receptor agonists, and that it will continue evaluating the evidence.

Merck, known as MSD outside of the United States and Canada, announced the U.S. Food and Drug Administration has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemoradiotherapy for the treatment of patients with FIGO 2014 Stage III-IVA cervical cancer.

Ardelyx, Inc. announced that on January 10, 2024, the compensation committee of the company’s board of directors granted two new non-executive employees options to purchase an aggregate of 23,580 shares of the company’s common stock, and granted three new non-executive employees an aggregate of 33,300 Restricted Stock Units.

Today marks a turning point in the battle against Alzheimer’s disease as Darmiyan, Inc., a leading company in brain health innovation announces the FDA’s approval of its first-in-class (De Novo) clinical test, BrainSee.

XVIVO Perfusion AB Invitation to attend XVIVO’s conference call regarding the presentation of the Report on Operations 2023.